Biggest gainers and losers for May 4-8, 2026

BioPharma DiveGSK cuts deal with Sino to broaden reach of hepatitis B drug

Endpoints NewsDaiichi eyes almost $15B in oncology sales by 2030 in ADC franchise push

Endpoints NewsNew home for Novo's Parkinson's cell therapy; GSK turns to China for hep B drug

Clinical OMICsBrain-Controlled Hearing Aid Singles Out Voices in a Crowd

BioWorldBiggest gainers and losers for May 4-8, 2026

Endpoints NewsInhibrx says combo therapy shrank more tumors than Merck's Keytruda alone

FierceBiotechAmid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data

FierceBiotechDaiichi Sankyo targets global top 5 oncology rank by 2035, $1.3B efficiency drive in new 5-year plan

BioPharma DiveInhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial

FDA News ReleasesFDA Advances Drug Repurposing to Address Unmet Medical Needs

Endpoints NewsBraveheart Bio's Hengrui-licensed cardiac drug scores second clinical win

BioPharma DiveBiotech layoffs are easing, but is the worst over?